Journal Browser Advanced Search Help
Journal Browser Advanced search HELP
J Obes Metab Syndr. 2019 Mar;28(1):18-29. English. Review. https://doi.org/10.7570/jomes.2019.28.1.18
Jung CH , Mok JO .
Division of Endocrinology and Metabolism, Department of Internal Medicine, Soonchunhyang University Bucheon Hospital, Soonchunhyang University College of Medicine, Bucheon, Korea. hanna@schmc.ac.kr
Abstract

The only known, effective intervention for non-alcoholic fatty liver disease (NAFLD) is weight loss, and there is no approved pharmacotherapy. Recently, new hypoglycemic agents, such as sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RAs), and their effects on NAFLD have received substantial interest. Herein, we review the currently available human studies regarding the effects of SGLT2 inhibitors and GLP-1RAs on NAFLD/non-alcoholic steatohepatitis in patients with type 2 diabetes mellitus, and we describe the possible mechanisms explaining the positive effects of these agents on NAFLD.

Copyright © 2019. Korean Association of Medical Journal Editors.